Ophthalmology Times

The US Food and Drug Administration (FDA) has approved biosimilar to Eylea, aflibercept-mrbb (Ahzantive), for the treatment of patients with age-related neovascular (wet) macular degeneration (nAMD). The biosimilar has also been approved for treatment in patients with serious retinal diseases such as diabetic macular edema (DME), diabetic retinopathy (DR) and macular edema following retinal vein occlusion (RVO). Read More: https://lnkd.in/ezv6gnVE

An overview of real-world geographic atrophy data: Durga Borkar, MD, MMCi, recently discussed the quality data (Qdata, Verana Health) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data. Read more: https://ow.ly/YP1V50StP9Q

Repeated 0.1-ml intravireal injections of lampalizumab (RG 7417, Genentech), antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D seem to be associated with a low risk of elevated intraocular pressure (IOP) in patients with geographic atrophy (GA), according to Neil Bressler, MD, and colleagues. He is from Johns Hopkins University School of Medicine, Baltimore. Historically, anti-vascular endothelial growth factor (VEGF) agents have been reported to cause IOP elevations that return to normal after about 30 minutes following 0.05-ml injections. However, the IOP elevations have become chronic in a small percentage of patients. Read More: https://ow.ly/9WVO50StPih

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has again recommended the refusal of marketing authorizations for Apellis’ Syfovre (pegcetacoplan). Apellis stated it plans on seeking re-examination of Syfovre and a final opinion is expected in the fourth quarter of 2024. Read More: https://lnkd.in/eB3EzDjU

Happy July 4th! Celebrate this Independence Day with pride and joy! Ophthalmology Times wishes everyone a wonderful holiday filled with safety and happiness. #FourthOfJuly #IndependenceDay #Ophthalmology #EyeHealth #Vision

In a recent article for Opthalmology Times, Dagny Zhu, MD, discussed the importance of screening for dry eye disease in patients who have undergone cataract surgery, as well as IOLs that may suit them best. "A healthy ocular surface has an impact on all aspects of cataract surgery. As IOL technology evolves to deliver even more refined visual results, treating DED before surgery becomes increasingly crucial. Fortunately, we have a plethora of OTC and prescription therapies to help prepare patients for optimal outcomes. At the same time, enhanced monofocal IOLs may help make increased freedom from glasses attainable for more of our patients." Read More: https://ow.ly/iSXg50SsLVi

Ashley Brissette, MD, MSc, FRCSC, team ophthalmologist for the New York Rangers of the NHL sat down to talk about eye injuries in hockey and other professional sports, as well as advancements in prevention and treatment for the players. Watch: https://ow.ly/fWBv50StBJs

The new extended treatment intervals for nAMD and DME open exciting possibilities for patients. We’ve planned a lively CME conversation with experts Arshad M. Khanani, MD, MA, FASRS; Carl Danzig, MD, FASRS; and Jennifer Lim, MD, FARVO. Learn more: https://bit.ly/45Lje33 #aao2024

Vicki Chan, MD, sat down with Ophthalmology Times to discuss the role that social media plays in medicine (and ophthalmology, of course), such as in patient education and combating misinformation. Chan also touches upon the innovative ways social media platforms can be used to connect audiences with physicians in this interview with Group Editorial Director Sheryl Stevenson. Watch: https://ow.ly/FMeI50SsLc3

The US Food and Drug Administration (FDA) has approved biosimilar to Eylea, aflibercept-mrbb (Ahzantive), for the treatment of patients with age-related neovascular (wet) macular degeneration (nAMD). The biosimilar has also been approved for treatment in patients with serious retinal diseases such as diabetic macular edema (DME), diabetic retinopathy (DR) and macular edema following retinal vein occlusion (RVO). Read More: https://ow.ly/XKG150StHGN